A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO/PACLITAXEL-CONTROLLED STUDY OF BATIRAXCEPT IN COMBINATION WITH WEEKLY PACLITAXEL IN PATIENTS WITH PLATINUM-RESISTANT RECURRENT OVARIAN CANCER (GOG-3059/ENGOT OV-66)

被引：1

作者：

Fuh, Katherine ^{[1
]}

Moore, Kathleen ^{[2
]}

Baert, Thais ^{[3
]}

Herzog, Thomas ^{[4
]}

Cibula, David ^{[5
,6
]}

Liu, Joyce ^{[7
]}

Eberst, Laurianne ^{[8
]}

Lewin, Sharon ^{[9
]}

Secord, Angeles Alvarez ^{[10
]}

Sehouli, Jalid ^{[11
]}

Myers, Tashanna ^{[12
]}

Bamias, Aristotelis ^{[13
]}

Rimel, B. J. ^{[14
]}

Colombo, Nicoletta ^{[15
]}

Franke, Amy ^{[16
]}

Shoop, Dipti ^{[17
]}

De Giorgi, Ugo ^{[18
]}

Pikiel, Joanna ^{[19
]}

Bowen, Rebecca ^{[20
]}

Gonzalez-Martin, Antonio ^{[21
]}

机构：

[1] Univ Calif San Francisco, Ob Gyn, San Francisco, CA 94143 USA

[2] Univ Oklahoma, Hlth Sci Ctr, Dept Gynecol Oncol, Stephenson Canc Ctr,Div Obstet & Gynecol, Oklahoma City, OK USA

[3] UZ Leuven, Ob Gyn, Leuven, Belgium

[4] Univ Cincinnati, Ctr Canc, Obstet & Gynecol, Cincinnati, OH USA

[5] Charles Univ Prague, Fac Med 1, Prague, Czech Republic

[6] Gen Univ Hosp, Dept Obstet & Gynecol, Prague, Czech Republic

[7] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA

[8] Inst Cancerol Strasbourg Europe, Oncol, Lyon, France

[9] HolyName Patricia Lynch Canc Ctr, Gynecol Oncol, Teaneck, NJ USA

[10] Duke, Ob Gyn, Durham, NC USA

[11] Charite Univ Med Berlin, Dept Gynecol, Ctr Oncol Surg, Campus Virchow Klinikum, Berlin, Germany

[12] Baystate Med Ctr, Div Gynecol Oncol, Obstet & Gynecol, Springfield, MA 01199 USA

[13] Attikon Gen Univ Hosp Athens, Oncol, Athens, Greece

[14] Cedars Sinai Med Ctr, Gynecol Oncol, Los Angeles, CA 90048 USA

[15] Univ Milano Bicocca, European Inst Oncol IRCCS, Dept Gynecol Oncol, Milan, Italy

[16] Aravive, Oncol, Houston, TX USA

[17] Aravive, Biol, Houston, TX USA

[18] Stituto Romagnolo Studio Tumori IRST Dino Amadori, Urogynecol, Meldola, Italy

[19] Reg Ctr Oncol, Dept Chemotherapy, Gdansk, Poland

[20] Royal United Hosp Bath, Oncol, Bath, Avon, England

[21] Clin Univ Navarra, Med Oncol, Madrid, Spain

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2022年 / 32卷

关键词：

D O I：

10.1136/ijgc-2022-igcs.532

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TP023/#156

引用

页码：A234 / A235

页数：2

共 50 条

[21] Paclitaxel injectable emulsion: Phase 2a study of weekly administration in patients with platinum-resistant ovarian cancer
Lissianskaya, A
Gershanovich, M
Ognerubov, N
Golubeva, O
Pratt, J
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 460S - 460S
[22] Phase III INNOVATE study of tumor treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer (ENGOT-ov50/BGOG study groups)
Vergote, Ignace
CANCER RESEARCH, 2019, 79 (13)
[23] Chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase 3 trial
Mahner, S.
Lueck, H. -J.
Grischke, E. -M.
Rau, J.
Gropp-Meier, M.
Schmalfeldt, B.
Meier, W.
Hasenburg, A.
Belau, A.
Vergote, I.
Zorr, A.
Huels, R.
Gerber, B.
du Bois, A.
Marme, F.
Hilpert, F.
Canzler, U.
Kurzeder, C.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 97 - 97
[24] TRINOVA-3/ENGOT-ov-2/GOG-3001: A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF TREBANANIB PLUS CARBOPLATIN/PACLITAXEL AS FIRST-LINE TREATMENT IN ADVANCED OVARIAN CANCER
Vergote, I.
Scambia, G.
O'Malley, D. M.
Van Calster, B.
del Campo, J. M.
Meier, W.
Bamias, A.
Colombo, N.
Wenham, R. M.
Covens, A.
Marth, C.
Mirza, M. Raza
Kroep, J. R.
Ma, H.
Pickett, C. A.
Monk, B. J.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 13 - 14
[25] Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)
Arend, Rebecca C.
Monk, Bradley J.
Shapira-Frommer, Ronnie
Haggerty, Ashley F.
Alvarez, Edwin A.
Amit, Amnon
Secord, Angeles Alvarez
Muller, Carolyn
Herraez, Antonio Casado
Herzog, Thomas J.
Tewari, Krishnansu S.
Cohen, Joshua G.
Huang, Marilyn
Yachnin, Adelya
Holeman, Laura L.
Ledermann, Jonathan A.
Minei, Tamar Rachmilewitz
Buyse, Marc
Shmueli, Shifra Fain
Lavi, Michal
Harats, Dror
Penson, Richard T.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (02) : 170 - 179
[26] A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)
Mirza, M. R.
Monk, B. J.
Oza, A.
Mahner, S.
Redondo, A.
Fabbro, M.
Ledermann, J.
Lorusso, D.
Vergote, I. B.
Rosengarten, O.
Berek, J.
Herrstedt, J.
Tinker, A. V.
Dubois, A.
Gonzalez Martin, A.
Follana, P.
Benigno, B.
Rimel, B. J.
Agarwal, S.
Matulonis, U.
ANNALS OF ONCOLOGY, 2016, 27
[27] A Randomized, Double-Blind Phase 3 Trial of Maintenance Therapy With Niraparib vs Placebo in Patients With Platinum-Sensitive Recurrent Ovarian Cancer (ENGOT-OV16/NOVA Trial)
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 3 - 5
[28] Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
Vergote, Ignace
Scambia, Giovanni
O'Malley, David M.
Van Calster, Ben
Park, Sang-Yoon
del Campo, Josep M.
Meier, Werner
Bamias, Aristotelis
Colombo, Nicofetta
Wenham, Robert M.
Covens, Al
Marth, Christian
Mirza, Mansoor Raza
Kroep, Judith R.
Ma, Haijun
Pickett, Cheryl A.
Monk, Bradley J.
LANCET ONCOLOGY, 2019, 20 (06): : 862 - 876
[29] OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer
McNeish, I. A.
Moreno, V.
Jayson, G.
Roxburgh, P.
Barretina Ginesta, M. P.
Garcia-Donas, J.
Anton Torres, A.
Michael, A.
Brown, R.
Krige, D.
Bendall, J.
Di Genova, G.
McElwaine-Johnn, H.
ANNALS OF ONCOLOGY, 2019, 30 : 421 - 421
[30] A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial).
Matulonis, Ursula
Mahner, Sven
Wenham, Robert Michael
Ledermann, Jonathan A.
Monk, Bradley J.
Campo, Jose Maria Dei
Berek, Jonathan S.
Vergote, Ignace
Fabbro, Michel
Katsaros, Dionyssios
Marth, Christian
Lorusso, Domenica
Herrstadt, Jorn
Agarwal, Shefali
Martell, Robert E.
Mirza, Mansoor Raza
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 3 4 5 →